Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30
   PubMed Web of Science ®Google Scholar
• Ye DW, Zhang HL. Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma. OncoTargets Ther 2014;7:925–35
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524–48
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Mattes RH. Combination of surgery and immunotherapy in metastatic renal cell carcinoma. W J Urol 2005;23:191–5
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865–75
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China, 2011. Chin J Cancer Res 2015;27:2
   Google Scholar
• Hollingsworth JM, Miller DC, Daignault S, et al. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98:1331–4
   PubMed Web of Science ®Google Scholar
• Lam JS, Leppert JT, Belldegrun AS, et al. Novel approaches in the therapy of metastatic renal cell carcinoma. W J Urol 2005;23:202–12
   PubMed Web of Science ®Google Scholar
• Guo J, Ma J, Sun Y. Chinese guidelines on the management of renal cell carcinoma (2015 edition). Ann Translat Med 2015;3:279
   Google Scholar
• Hartmann J, Bokemeyer C. Chemotherapy for renal cell carcinoma. Anticancer Res 1999;19:1541–3
   PubMed Web of Science ®Google Scholar
• Sun M, Shariat SF, Trinh Q-D, et al. An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. Ther Adv Urol 2013;5:121–8
   PubMedGoogle Scholar
• Stillman I, Ambavane A, Cislo P. A cost-effectiveness analysis of axitinib and sorafenib for 2nd line treatment of advanced renal cell carcinoma after failure of cytokines in the United States. Value Health 2013;16:A410
   Web of Science ®Google Scholar
• Özer-Stillman I, Ambavane A, Cislo P. An economic analysis of axitinib and sorafenib for second-line treatment of cytokine-refractory patients with advanced renal cell carcinoma in the United States (US). Journal of Clinical Oncology 2013; 31 (suppl 15)
   Google Scholar
• Petrou P. Cost-effectiveness analysis of axitinib through a probabilistic decision model. Expert Opin Pharmacother 2015;16:1233–43
   PubMed Web of Science ®Google Scholar
• Paplomata E, Zelnak A, O’Regan R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Ccancer Res Treat 2013;140:453–62
   PubMed Web of Science ®Google Scholar
• Markouri A, Geitona M, Kousoulakou H, et al. Treatment pathways and associated costs of advanced or metastatic ALK-positive non-small cell lung cancer in Greece. Pharmacoeconomics 2016;1:109
   PubMedGoogle Scholar
• Schabert V, Chen Y, Sun K, et al. Relationship between progression-free survival (PFS) and overall survival (OS) in hormone receptor-negative metastatic breast cancer (MBC): a comparative effectiveness analysis using linked claims, EMR, and mortality records. Value Health. 2014;17:A69
   Web of Science ®Google Scholar
• Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013;14:1287–94
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931–9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:2765–72
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803–13
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1814–23
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Alyasova A, Ye D, et al. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Ann Oncol 2016;27:441–8
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449–56
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013;31:3791–9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:286–96
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722–31
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24
   PubMed Web of Science ®Google Scholar
• Eichelberg C, Vervenne WL, De Santis M, et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur Urol 2015;68:837–47
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34
   PubMed Web of Science ®Google Scholar
• Procopio G, Verzoni E, Bracarda S, et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Ann Oncol 2013;24:2967–71
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012;12:9
   PubMed Web of Science ®Google Scholar
• The Integrated Management Platform of Beijing Medicine Sunshine Purchase
   Google Scholar
• Shanghai Municipal Human Resources and Social Security Bureau
   Google Scholar
• Data on file. Pfizer China, Inc.; 2018
   Google Scholar
• Inlyta (axitinib). Prescribing information. Pfizer; 2012
   Google Scholar
• Sutent (sunitinib malate). Prescribing information. Pfizer; 2006
   Google Scholar
• Nexavar (sorafenib). Prescribing information. Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals; 2005
   Google Scholar
• He J, Wen F, Yin X, et al. Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer. Anticancer Drugs 2013;24:754–8
   PubMed Web of Science ®Google Scholar
• Tan C, Peng L, Zeng X, et al. Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China. PLoS One 2013;8:e83396
   PubMed Web of Science ®Google Scholar
• Wu B, Chen H, Shen J, et al. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China. Clin Therapeut 2011;33:1446–55
   PubMed Web of Science ®Google Scholar
• Wu B, Dong B, Xu Y, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One 2012;7:e32530
   PubMed Web of Science ®Google Scholar
• De Groot S, Blommestein HM, Redekop WK, et al. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: a real-world cost-effectiveness analysis of sequential first- and second-line treatments. PLoS One 2017;12:e0177364
   PubMed Web of Science ®Google Scholar
• Miguel L, Luz R. Economic evaluation of axitinib for second line treatment in adult patients with advanced renal cell carcinoma - the Portuguese case. ISPOR 17th Annual European Congress, November 8–12, 2014, Amsterdam RAI, Amsterdam; 2014
   Google Scholar
• Romero Prada M, Huerfano L, Roa Cardenas N. Cost-effectiveness analysis of using everolimus or axinitinb in patients with metastatic renal cell carcinoma who have failed to use of pazopanib or sunitinib in first-line treatment. Value Health 2016;19:A735
   Web of Science ®Google Scholar
• Chandiwana D, Perrin A, Sherman S. A cost effectiveness analysis of everolimus compared with axitinib in the treatment of metastatic renal cell carcinoma in the United Kingdom. Value Health 2014;17:A640
   PubMed Web of Science ®Google Scholar
• Cai W, Kong W, Dong B, et al. Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma. Chin J Cancer 2017;36:64
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(suppl 5):v58–v68
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 3.2015. J Natl Comprehens Cancer Netw 2015;13:151–9
   PubMedGoogle Scholar
• Sherman S, Amzal B, Calvo E, et al. An indirect comparison of everolimus versus axitinib in US patients with advanced renal cell carcinoma in whom prior sunitinib therapy failed. Clin Therapeut 2015;37:2552–9
   Web of Science ®Google Scholar
• Vogelzang NJ, Pal SK, Signorovitch JE, et al., editors. Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: a retrospective chart review. ASCO Annual Meeting Proceedings, Chicago, Illinois, May 29-June 2, 2015
   Google Scholar
• Reuters Staff. China signals price cuts for cancer drugs, imports: Reuters; 2016. Available at: http://www.reuters.com/article/us-china-pharmaceuticals/china-signals-price-cuts-for-cancer-drugs-imports-idUSKCN0WB0FI [Last accessed October 16, 2017]
   Google Scholar